NCT01201096

Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)

Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: University of Jena · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to show the tumor free long term survival of patients with isolated non-resectable liver metastases of neuroendocrine tumors after neo-adjuvant radio receptor treatment and following liver transplantation.

Detailed description

Matching patient will be treated neo-adjuvant at the hospital with 177 Lutetium peptide receptor radiotherapy in two following courses. After this treatment it will follow the liver transplantation within 9 month as postmortal or living donor liver transplantation. Under certain conditions concerning the evaluation examinations patients can be included in the study. Most important factors are no evidence of disease outside the liver, removed primary tumor, patients between 18 and 60 years, no curative surgical resection of the liver metastasis possible.

Conditions

• Liver
• Metastasis
• Neuroendocrine Tumors

Interventions

Type	Name	Description
RADIATION	177Lutetium	two cycles of 177Lutetium radioreceptor therapy within two month
PROCEDURE	Liver transplantation	about 9 month after finishing the receptor therapy liver transplantation takes place

Timeline

• Start date: 2010-09-01
• Primary completion: 2015-09-01
• Completion: 2018-09-01
• First posted: 2010-09-14
• Last updated: 2010-09-23

Locations

2 sites across 1 country: Germany